Yinfeng Lyu

Dr. Yinfeng Lyu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CFChenchen Feng
Chenchen Feng
YLYuqing Li
Yuqing Li
LKLi Kunping
Li Kunping
YLYinfeng Lyu
Yinfeng Lyu
WZWenhui Zhu
Wenhui Zhu
HWHui Wen
Hui Wen
Background: Kinases play critical role in clear-cell renal cell carcinoma (ccRCC). We aim to exploit novel kinase that is both protumorigenic and drugable in ccRCC. Methods: Reproduction of public datasets with validation using microarray was performed to identify candidate gene. Functionality was studied using multi-omics with validation in vitro and in vivo. Results: 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 (PFKFB4) was differentially expressed showing significantly higher expression in tumor than in normal kidney. PFKFB4 overexpression was associated with advanced tumor grade, stage and worsened prognosis. PFKFB4-knockdown significantly impaired fitness in cell proliferation, migration and wound healing. Despite being recurrently deleted on 3p, PFKFN4 mRNA remained actively transcribed by HIF1α. Metabolomics showed overexpressed PFKFB4 showed enriched metabolites in pentose phosphate pathway (PPP). Phosphoproteomics and immunoprecipitation showed PFKFB4 also phosphorylated NCOA3 which interacted with FBP1 to counteract overactive PPP flux, forming a regulatory loop. PFKFB4-knockdown overcame resistance to Sunitinib in vitro and in vivo both in xenograft and tail-vein injection murine models. Conclusion: We concluded PFKFB4 was associated with PPP activity and the fine-tuning of which was mediated by its phosphorylation of NCOA3. Targeting PFKFB4 held promise to combat resistance to Sunitinib.

28 May 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
CFChenchen Feng
Chenchen Feng
YLYinfeng Lyu
Yinfeng Lyu
LGLingxiao Gong
Lingxiao Gong
JWJing Wang
Jing Wang
Renal cell carcinoma (RCC) is a common cancer of the urinary system. The potential therapeutic effects of certain natural products against renal cell carcinoma have been reported both in vivo and in vitro, but no reviews have been published classifying and summarizing the mechanisms of action of various natural products. In this study, we used PubMed and Google Scholar to collect and screen the recent literature on natural products with anti-renal-cancer effects. The main mechanisms of action of these products include the induction of apoptosis, inhibition of angiogenesis, inhibition of metastasis and reduction of drug resistance. In total, we examined more than 30 natural products, which include kahweol acetate, honokiol, englerin A and epigallocatechin-3-gallate, among others, have demonstrated a variety of anti-renal-cancer effects. In conclusion, natural products may have a wider application in kidney cancer than previously believed and are potential candidates for treatment in RCC.

14 September 2022 in Apoptosis
Verified
Journal Article
Closed access
PDF file
LKLi Kunping
Li Kunping
LTLinyi Tan
Linyi Tan
YLYuqing Li
Yuqing Li
YLYinfeng Lyu
Yinfeng Lyu
XZXinyi Zheng
Xinyi Zheng
CFChenchen Feng
Chenchen Feng